CompletedPhase 2NCT03921554
JAK Inhibitor Treatment in AGS
Studying Type 1 interferonopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Adeline Vanderver, MD
- Principal Investigator
- Adeline Vanderver, MDChildren's Hospital of Philadelphia
- Intervention
- Baricitinib(drug)
- Enrollment
- 54 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2024
Study locations (1)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03921554 on ClinicalTrials.gov